Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0234 USD
−49.84 M USD
0.00 USD
1.21 B
About CytoDyn Inc.
Sector
CEO
Jacob P. Lalezari
Headquarters
Vancouver
Website
Founded
2002
FIGI
BBG000BYS4X7
CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CYDY is 0.1148 USD — it has decreased by −0.77% in the past 24 hours. Watch CytoDyn Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange CytoDyn Inc. stocks are traded under the ticker CYDY.
CYDY stock has fallen by −1.86% compared to the previous week, the month change is a −8.66% fall, over the last year CytoDyn Inc. has showed a −30.63% decrease.
CYDY reached its all-time high on Jun 30, 2020 with the price of 10.0100 USD, and its all-time low was 0.0552 USD and was reached on Feb 11, 2019. View more price dynamics on CYDY chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYDY stock is 14.94% volatile and has beta coefficient of 0.69. Track CytoDyn Inc. stock price on the chart and check out the list of the most volatile stocks — is CytoDyn Inc. there?
Today CytoDyn Inc. has the market capitalization of 142.60 M, it has decreased by −2.56% over the last week.
Yes, you can track CytoDyn Inc. financials in yearly and quarterly reports right on TradingView.
CytoDyn Inc. is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
CYDY net income for the last quarter is 19.23 M USD, while the quarter before that showed −16.79 M USD of net income which accounts for 214.54% change. Track more CytoDyn Inc. financial stats to get the full picture.
No, CYDY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2024, the company has 9.00 employees. See our rating of the largest employees — is CytoDyn Inc. on this list?
Like other stocks, CYDY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CytoDyn Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CytoDyn Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CytoDyn Inc. stock shows the strong sell signal. See more of CytoDyn Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.